Drug Profile

KT 621

Alternative Names: KT-621

Latest Information Update: 23 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kymera Therapeutics
Class Anti-infectives; Anti-inflammatories; Antiasthmatics; Skin disorder therapies; Small molecules
Mechanism of Action STAT6 transcription factor degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Asthma; Atopic dermatitis
Phase I Immunological disorders

Most Recent Events

13 Jan 2026 Phase-II clinical trials in Asthma (PO)
11 Dec 2025 KT 621 receives Fast Track designation for Atopic dermatitis [PO,once-daily] in USA
04 Nov 2025 Kymera Therapeutics completes enrollment in a phase-Ib BroADen trial in Atopic dermatitis in USA (PO) before November 2025 (NCT06945458)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com